Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients.
Ocular toxoplasmosis
Outcome
RD Congo
Treatment
Trimethoprim/Sulfamethoxazole
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
21
03
2023
accepted:
24
10
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the "classic' treatment therapy (Pyrimethamine/Sulfadiazine). A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.
Sections du résumé
BACKGROUND
BACKGROUND
Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the "classic' treatment therapy (Pyrimethamine/Sulfadiazine).
METHODS
METHODS
A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients.
RESULTS
RESULTS
54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment.
CONCLUSION
CONCLUSIONS
TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.
Identifiants
pubmed: 37907920
doi: 10.1186/s12886-023-03183-x
pii: 10.1186/s12886-023-03183-x
pmc: PMC10617208
doi:
Substances chimiques
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Pyrimethamine
Z3614QOX8W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440Informations de copyright
© 2023. The Author(s).
Références
Ocul Immunol Inflamm. 2020;28(2):249-255
pubmed: 30806556
Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):95-108
pubmed: 22712598
Am J Ophthalmol. 2014 Apr;157(4):762-766.e1
pubmed: 24388839
Heliyon. 2021 Oct 27;7(11):e08265
pubmed: 34778574
J Fr Ophtalmol. 2019 Oct;42(8):900-906
pubmed: 31248609
Drugs R D. 2017 Dec;17(4):523-544
pubmed: 28879584
Sci Rep. 2021 Feb 4;11(1):3137
pubmed: 33542439
J Glaucoma. 2005 Feb;14(1):3-10
pubmed: 15650597
Ocul Immunol Inflamm. 2012 Apr;20(2):68-75
pubmed: 22409558
Ophthalmology. 2007 Mar;114(3):616
pubmed: 17324702
Prog Retin Eye Res. 2014 Mar;39:77-106
pubmed: 24412517
Cochrane Database Syst Rev. 2016 May 20;(5):CD002218
pubmed: 27198629
J Curr Ophthalmol. 2016 Dec 28;29(2):120-125
pubmed: 28626822
Ophthalmology. 2005 Nov;112(11):1876-82
pubmed: 16171866
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2541
pubmed: 24278490
Sci Rep. 2021 Jan 13;11(1):1035
pubmed: 33441899
Can J Ophthalmol. 2013 Aug;48(4):e94-5
pubmed: 23931496
Acta Trop. 2018 Sep;185:52-62
pubmed: 29704469
Ophthalmologica. 2011;225(1):1-20
pubmed: 20693817
Ocul Immunol Inflamm. 2006 Apr;14(2):73-85
pubmed: 16597536
J Clin Med. 2021 Mar 05;10(5):
pubmed: 33807871
Eye (Lond). 2009 May;23(5):1090-3
pubmed: 18617902
Clin Microbiol Rev. 2018 Sep 12;31(4):
pubmed: 30209035
Eye (Lond). 2006 Sep;20(9):1080-2
pubmed: 16200054
Ocul Immunol Inflamm. 2011 Oct;19(5):314-20
pubmed: 21970662
J Ocul Pharmacol Ther. 2015 Nov;31(9):511-7
pubmed: 26226199
PLoS Negl Trop Dis. 2016 May 02;10(5):e0004685
pubmed: 27136081
Pathog Glob Health. 2017 Oct;111(7):333-342
pubmed: 28948861
Ocul Immunol Inflamm. 2018;26(2):317-323
pubmed: 27598330
Eye (Lond). 2008 Sep;22(9):1201-2; author reply 1200-1
pubmed: 18259204
Syst Rev. 2021 Jul 19;10(1):206
pubmed: 34275483